Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Edwards Lifesciences CorpEW · Entity 3026 | Director | May 02, 2024 | May 02, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Edwards Lifesciences Corp
Report date May 02, 2024 · Filed May 02, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 4,485.82 |
Ending reported balance
After 2024-05-02 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2024-05-02 · Exercise / conversion · Acquired 29,350 · Balance 33,835.82 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 15, 2023. Row 2 · 2024-05-02 · Sale · Disposed 12,207 · Balance 21,628.82 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 15, 2023. F2: This transaction was executed in multiple trades at prices ranging from $84.865 to $85.420. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Row 3 · 2024-05-02 · Sale · Disposed 17,143 · Balance 4,485.82 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 15, 2023. F3: This transaction was executed in multiple trades at prices ranging from $83.860 to $84.860. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. |
| Employee Stock Option (Right to Acquire)SEC Table II · derivative / convertible security · Conversion / exercise price $36.75 · Expires 2024-05-10 | Direct | 0 |
Reported balance
After 2024-05-02 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2024-05-02 · Exercise / conversion · Disposed 29,350 · Balance 0 |
| Common StockSEC Table I · non-derivative | IndirectBy Living Trust | 4,038,377 |
Reported balance
Holding disclosure · report date 2024-05-02 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 4,038,377 |
Filing footnotes · ownership attribution and instrument terms
F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 15, 2023.
F2: This transaction was executed in multiple trades at prices ranging from $84.865 to $85.420. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
F3: This transaction was executed in multiple trades at prices ranging from $83.860 to $84.860. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 15, 2019 Filed Nov 18, 2019 18:37 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 32,850 | $35.79 | $1,175,537.25 |
DisclosureSEC source: 0001225208-19-014617 · doc4.xml · nonDerivative · entry 1 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,769.82 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 26, 2019. Read SEC document |
| October 30, 2019 Filed Oct 31, 2019 16:09 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 32,850 | $0.00 Strike: $35.79 | $0.00 |
DisclosureSEC source: 0001225208-19-013958 · doc4.xml · derivative · entry 8 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 229,950 Underlying: Common Stock · 32,850 shares Expires 2020-05-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 26, 2019. Read SEC document |
| October 30, 2019 Filed Oct 31, 2019 16:09 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GiftCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-013958 · doc4.xml · nonDerivative · entry 6 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Living Trust Disclosed balance after: 795,400 Read SEC document |
| October 30, 2019 Filed Oct 31, 2019 16:09 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GiftCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-013958 · doc4.xml · nonDerivative · entry 5 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,919.82 Read SEC document |
| October 30, 2019 Filed Oct 31, 2019 16:09 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 13,115 | $238.75 | $3,131,228.55 |
DisclosureSEC source: 0001225208-19-013958 · doc4.xml · nonDerivative · entry 4 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,919.82 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 26, 2019. F4 · price: This transaction was executed in multiple trades at prices ranging from $238.24 to $239.23. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| October 30, 2019 Filed Oct 31, 2019 16:09 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 5,900 | $239.52 | $1,413,154.43 |
DisclosureSEC source: 0001225208-19-013958 · doc4.xml · nonDerivative · entry 3 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,034.82 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 26, 2019. F3 · price: This transaction was executed in multiple trades at prices ranging from $239.36 to $239.91. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| October 30, 2019 Filed Oct 31, 2019 16:09 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 3,835 | $237.80 | $911,963.00 |
DisclosureSEC source: 0001225208-19-013958 · doc4.xml · nonDerivative · entry 2 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,934.82 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 26, 2019. F2 · price: This transaction was executed in multiple trades at prices ranging from $237.24 to $238.20. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| October 30, 2019 Filed Oct 31, 2019 16:09 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 32,850 | $35.79 | $1,175,537.25 |
DisclosureSEC source: 0001225208-19-013958 · doc4.xml · nonDerivative · entry 1 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,769.82 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 26, 2019. Read SEC document |
| September 10, 2019 Filed Sep 11, 2019 18:05 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 32,850 | $0.00 Strike: $35.79 | $0.00 |
DisclosureSEC source: 0001225208-19-012311 · doc4.xml · derivative · entry 14 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 262,800 Underlying: Common Stock · 32,850 shares Expires 2020-05-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 26, 2019. Read SEC document |
| September 10, 2019 Filed Sep 11, 2019 18:05 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GiftCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-012311 · doc4.xml · nonDerivative · entry 12 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Living Trust Disclosed balance after: 785,400 Read SEC document |
| September 10, 2019 Filed Sep 11, 2019 18:05 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GiftCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-012311 · doc4.xml · nonDerivative · entry 11 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,919.82 Read SEC document |
| September 10, 2019 Filed Sep 11, 2019 18:05 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 8,400 | $216.43 | $1,818,012.84 |
DisclosureSEC source: 0001225208-19-012311 · doc4.xml · nonDerivative · entry 10 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,919.82 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 26, 2019. F10 · price: This transaction was executed in multiple trades at prices ranging from $216.01 to $216.96. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 10, 2019 Filed Sep 11, 2019 18:05 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 3,656 | $217.42 | $794,901.78 |
DisclosureSEC source: 0001225208-19-012311 · doc4.xml · nonDerivative · entry 9 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,319.82 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 26, 2019. F9 · price: This transaction was executed in multiple trades at prices ranging from $217.0150 to $217.93. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 10, 2019 Filed Sep 11, 2019 18:05 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 2,400 | $215.66 | $517,592.40 |
DisclosureSEC source: 0001225208-19-012311 · doc4.xml · nonDerivative · entry 8 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,975.82 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 26, 2019. F8 · price: This transaction was executed in multiple trades at prices ranging from $214.98 to $215.97. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 10, 2019 Filed Sep 11, 2019 18:05 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 2,194 | $213.23 | $467,829.25 |
DisclosureSEC source: 0001225208-19-012311 · doc4.xml · nonDerivative · entry 7 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,375.82 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 26, 2019. F7 · price: This transaction was executed in multiple trades at prices ranging from $212.8150 to $213.80. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 10, 2019 Filed Sep 11, 2019 18:05 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 2,100 | $214.16 | $449,736.00 |
DisclosureSEC source: 0001225208-19-012311 · doc4.xml · nonDerivative · entry 6 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,569.82 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 26, 2019. F6 · price: This transaction was executed in multiple trades at prices ranging from $213.83 to $214.7050. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 10, 2019 Filed Sep 11, 2019 18:05 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 1,500 | $208.70 | $313,050.00 |
DisclosureSEC source: 0001225208-19-012311 · doc4.xml · nonDerivative · entry 5 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,669.82 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 26, 2019. F5 · price: This transaction was executed in multiple trades at prices ranging from $208.24 to $209.22. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 10, 2019 Filed Sep 11, 2019 18:05 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 1,200 | $211.10 | $253,315.56 |
DisclosureSEC source: 0001225208-19-012311 · doc4.xml · nonDerivative · entry 4 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,169.82 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 26, 2019. F4 · price: This transaction was executed in multiple trades at prices ranging from $210.56 to $211.48. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 10, 2019 Filed Sep 11, 2019 18:05 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 1,000 | $212.20 | $212,196.40 |
DisclosureSEC source: 0001225208-19-012311 · doc4.xml · nonDerivative · entry 3 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,369.82 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 26, 2019. F3 · price: This transaction was executed in multiple trades at prices ranging from $211.67 to $212.61. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 10, 2019 Filed Sep 11, 2019 18:05 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 400 | $209.74 | $83,894.00 |
DisclosureSEC source: 0001225208-19-012311 · doc4.xml · nonDerivative · entry 2 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,369.82 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 26, 2019. F2 · price: This transaction was executed in multiple trades at prices ranging from $209.2350 to $210.12. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 10, 2019 Filed Sep 11, 2019 18:05 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 32,850 | $35.79 | $1,175,537.25 |
DisclosureSEC source: 0001225208-19-012311 · doc4.xml · nonDerivative · entry 1 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,769.82 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 26, 2019. Read SEC document |
| August 22, 2019 Filed Aug 23, 2019 00:51 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 32,850 | $0.00 Strike: $35.79 | $0.00 |
DisclosureSEC source: 0001225208-19-011835 · doc4.xml · derivative · entry 15 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 361,350 Underlying: Common Stock · 32,850 shares Expires 2020-05-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 22, 2019 Filed Aug 23, 2019 00:51 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GiftCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-011835 · doc4.xml · nonDerivative · entry 13 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Living Trust Disclosed balance after: 775,400 Read SEC document |
| August 22, 2019 Filed Aug 23, 2019 00:51 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GiftCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-011835 · doc4.xml · nonDerivative · entry 12 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,919.82 Read SEC document |
| August 22, 2019 Filed Aug 23, 2019 00:51 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 9,825 | $216.37 | $2,125,812.65 |
DisclosureSEC source: 0001225208-19-011835 · doc4.xml · nonDerivative · entry 11 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,919.82 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 26, 2019. F11 · price: This transaction was executed in multiple trades at prices ranging from $215.84 to $216.8150. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 22, 2019 Filed Aug 23, 2019 00:51 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 2,600 | $214.25 | $557,046.62 |
DisclosureSEC source: 0001225208-19-011835 · doc4.xml · nonDerivative · entry 10 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,744.82 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 26, 2019. F10 · price: This transaction was executed in multiple trades at prices ranging from $213.62 to $214.57. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 22, 2019 Filed Aug 23, 2019 00:51 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 2,525 | $215.41 | $543,915.05 |
DisclosureSEC source: 0001225208-19-011835 · doc4.xml · nonDerivative · entry 9 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,344.82 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 26, 2019. F9 · price: This transaction was executed in multiple trades at prices ranging from $214.84 to $215.83. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 22, 2019 Filed Aug 23, 2019 00:51 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 2,099 | $220.76 | $463,369.99 |
DisclosureSEC source: 0001225208-19-011835 · doc4.xml · nonDerivative · entry 8 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,869.82 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 26, 2019. F8 · price: This transaction was executed in multiple trades at prices ranging from $220.12 to $221.08. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 22, 2019 Filed Aug 23, 2019 00:51 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 1,700 | $217.02 | $368,927.03 |
DisclosureSEC source: 0001225208-19-011835 · doc4.xml · nonDerivative · entry 7 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,968.82 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 26, 2019. F7 · price: This transaction was executed in multiple trades at prices ranging from $216.8450 to $217.55. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 22, 2019 Filed Aug 23, 2019 00:51 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 1,700 | $218.55 | $371,531.26 |
DisclosureSEC source: 0001225208-19-011835 · doc4.xml · nonDerivative · entry 6 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,668.82 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 26, 2019. F6 · price: This transaction was executed in multiple trades at prices ranging from $218.03 to $218.96. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 22, 2019 Filed Aug 23, 2019 00:51 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 800 | $219.65 | $175,722.56 |
DisclosureSEC source: 0001225208-19-011835 · doc4.xml · nonDerivative · entry 5 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,368.82 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 26, 2019. F5 · price: This transaction was executed in multiple trades at prices ranging from $219.09 to $220.01. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 22, 2019 Filed Aug 23, 2019 00:51 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 700 | $212.04 | $148,429.61 |
DisclosureSEC source: 0001225208-19-011835 · doc4.xml · nonDerivative · entry 4 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,168.82 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 26, 2019. F4 · price: This transaction was executed in multiple trades at prices ranging from $211.51 to $212.48. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 22, 2019 Filed Aug 23, 2019 00:51 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 601 | $221.34 | $133,023.12 |
DisclosureSEC source: 0001225208-19-011835 · doc4.xml · nonDerivative · entry 3 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,868.82 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 26, 2019. F3 · price: This transaction was executed in multiple trades at prices ranging from $221.13 to $222.62. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 22, 2019 Filed Aug 23, 2019 00:51 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 300 | $212.97 | $63,890.76 |
DisclosureSEC source: 0001225208-19-011835 · doc4.xml · nonDerivative · entry 2 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,469.82 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 26, 2019. F2 · price: This transaction was executed in multiple trades at prices ranging from $212.57 to $213.26. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 22, 2019 Filed Aug 23, 2019 00:51 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 32,850 | $35.79 | $1,175,537.25 |
DisclosureSEC source: 0001225208-19-011835 · doc4.xml · nonDerivative · entry 1 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,769.82 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 26, 2019. Read SEC document |
| August 22, 2019 Filed Sep 10, 2019 00:14 UTC Amendment | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 32,850 | $0.00 Strike: $35.79 | $0.00 |
DisclosureSEC source: 0001225208-19-012274 · doc4a.xml · derivative · entry 1 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 295,650 Underlying: Common Stock · 32,850 shares Expires 2020-05-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 09, 2019 Filed Jul 10, 2019 21:02 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 32,850 | $0.00 Strike: $35.79 | $0.00 |
DisclosureSEC source: 0001225208-19-010178 · doc4.xml · derivative · entry 8 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 328,500 Underlying: Common Stock · 32,850 shares Expires 2020-05-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 09, 2019 Filed Jul 10, 2019 21:02 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GiftCommon Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-010178 · doc4.xml · nonDerivative · entry 6 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Living Trust Disclosed balance after: 765,400 F5 · ownership.nature: These transactions include an additional 10,000 shares transferred to the Living Trust as a gift. Read SEC document |
| July 09, 2019 Filed Jul 10, 2019 21:02 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GiftCommon Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-010178 · doc4.xml · nonDerivative · entry 5 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,919.82 F5 · ownership.direct: These transactions include an additional 10,000 shares transferred to the Living Trust as a gift. Read SEC document |
| July 09, 2019 Filed Jul 10, 2019 21:02 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 11,200 | $189.44 | $2,121,703.36 |
DisclosureSEC source: 0001225208-19-010178 · doc4.xml · nonDerivative · entry 4 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,919.82 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 26, 2019. F4 · price: This transaction was executed in multiple trades at prices ranging from $188.8500 to $189.8400. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 09, 2019 Filed Jul 10, 2019 21:02 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 7,600 | $188.28 | $1,430,934.84 |
DisclosureSEC source: 0001225208-19-010178 · doc4.xml · nonDerivative · entry 3 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,119.82 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 26, 2019. F3 · price: This transaction was executed in multiple trades at prices ranging from $187.8400 to $188.8200. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 09, 2019 Filed Jul 10, 2019 21:02 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 4,050 | $189.93 | $769,218.12 |
DisclosureSEC source: 0001225208-19-010178 · doc4.xml · nonDerivative · entry 2 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,719.82 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 26, 2019. F2 · price: This transaction was executed in multiple trades at prices ranging from $189.8500 to $190.1900. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 09, 2019 Filed Jul 10, 2019 21:02 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 32,850 | $35.79 | $1,175,537.25 |
DisclosureSEC source: 0001225208-19-010178 · doc4.xml · nonDerivative · entry 1 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,769.82 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 26, 2019. Read SEC document |
| June 12, 2019 Filed Jun 13, 2019 00:45 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 32,850 | $0.00 Strike: $35.79 | $0.00 |
DisclosureSEC source: 0001225208-19-009189 · doc4.xml · derivative · entry 8 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 361,350 Underlying: Common Stock · 32,850 shares Expires 2020-05-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 12, 2019 Filed Jun 13, 2019 00:45 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 11,629 | $184.65 | $2,147,244.85 |
DisclosureSEC source: 0001225208-19-009189 · doc4.xml · nonDerivative · entry 5 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,919.82 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 26, 2019. F5 · price: This transaction was executed in multiple trades at prices ranging from $184.3600 to $185.3000. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 12, 2019 Filed Jun 13, 2019 00:45 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 8,321 | $183.82 | $1,529,591.18 |
DisclosureSEC source: 0001225208-19-009189 · doc4.xml · nonDerivative · entry 4 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,548.82 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 26, 2019. F4 · price: This transaction was executed in multiple trades at prices ranging from $183.3600 to $184.3500. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 12, 2019 Filed Jun 13, 2019 00:45 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 1,900 | $182.85 | $347,423.36 |
DisclosureSEC source: 0001225208-19-009189 · doc4.xml · nonDerivative · entry 3 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,869.82 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 26, 2019. F3 · price: This transaction was executed in multiple trades at prices ranging from $182.3200 to $183.3000. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 12, 2019 Filed Jun 13, 2019 00:45 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 1,000 | $186.41 | $186,410.10 |
DisclosureSEC source: 0001225208-19-009189 · doc4.xml · nonDerivative · entry 2 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,769.82 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 26, 2019. F2 · price: This transaction was executed in multiple trades at prices ranging from $185.6900 to $186.6700. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 12, 2019 Filed Jun 13, 2019 00:45 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 32,850 | $35.79 | $1,175,537.25 |
DisclosureSEC source: 0001225208-19-009189 · doc4.xml · nonDerivative · entry 1 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,769.82 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 26, 2019. Read SEC document |
| May 12, 2019 Filed May 14, 2019 22:24 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionPerformance Rights · Derivative | 11,119 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-007989 · doc4.xml · derivative · entry 4 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,119 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On May 12, 2016, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 7, 2019, the Compensation Committee of the Board of Directors determined that 75.77% of the target shares would vest as of May 12, 2019, and the actual number of shares vested are reflected on this Form and the balance of the award terminated. F1 · shares: On May 12, 2016, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 7, 2019, the Compensation Committee of the Board of Directors determined that 75.77% of the target shares would vest as of May 12, 2019, and the actual number of shares vested are reflected on this Form and the balance of the award terminated. F1 · price: On May 12, 2016, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 7, 2019, the Compensation Committee of the Board of Directors determined that 75.77% of the target shares would vest as of May 12, 2019, and the actual number of shares vested are reflected on this Form and the balance of the award terminated. F1 · derivative.exercise_date: On May 12, 2016, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 7, 2019, the Compensation Committee of the Board of Directors determined that 75.77% of the target shares would vest as of May 12, 2019, and the actual number of shares vested are reflected on this Form and the balance of the award terminated. F1 · derivative.expiration_date: On May 12, 2016, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 7, 2019, the Compensation Committee of the Board of Directors determined that 75.77% of the target shares would vest as of May 12, 2019, and the actual number of shares vested are reflected on this Form and the balance of the award terminated. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.